Russia Attracts More Multinational Pharmas As Emerging Markets Continue To Bloom
This article was originally published in PharmAsia News
Executive Summary
Indian drug maker Ranbaxy is moving swiftly to capitalize on Russian policies to encourage establishing a local production presence, signing a memorandum of understanding with Russia's Yaroslavl regional authority to help the province build a medical and pharmaceutical center. The "going local, going to regions" move could set a model for international pharma companies eying the Russian market, says a Russia biologics expert
You may also be interested in...
Back To Square One: India's J.B.Chemicals, Dr. Reddy's Terminate Russa Rx Deal
MUMBAI - Less than three months after agreeing to sell its Russia-CIS prescriptions business, Indian drug maker J.B. Chemicals & Pharmaceuticals Ltd. has called-off its deal with fellow Indian drug maker Dr. Reddy's Laboratories Ltd.
Back To Square One: India's J.B.Chemicals, Dr. Reddy's Terminate Russa Rx Deal
MUMBAI - Less than three months after agreeing to sell its Russia-CIS prescriptions business, Indian drug maker J.B. Chemicals & Pharmaceuticals Ltd. has called-off its deal with fellow Indian drug maker Dr. Reddy's Laboratories Ltd.
AstraZeneca To Break Ground In Russia As MNCs Build Stronger Base In The Country
Scheduled to break ground in April, AstraZeneca PLC's investment of more than $150 million into construction of a drug manufacturing plant in Russia indicates the U.K.-based firm's confidence and long-term commitment to the emerging Russian market